医药市场研究

药品又称为药物或药品。我们使用这些物质和化合物来预防、诊断、治疗或缓解疾病。它们可治疗人类和动物的疾病和健康状况。制药公司通过广泛的研究和测试来开发和制造这些药物。政府机构对它们的安全性、有效性和质量进行监管。

我们可以根据药物的用途将其分为不同的类别。我们还可以根据作用方式、化学成分和给药途径对药物进行分类。常见的药物包括处方药和非处方药、疫苗、生物制剂和仿制药。

政府机构监管处方药。患者只能凭有效处方购买这些药物。此处方必须来自合格的医疗保健提供者。提供者可以是医生、执业护士或牙医。提供者开这些药物来治疗复杂或慢性疾病。使用这些药物需要仔细的医疗监督。

非处方药，又称非处方药，也存在。消费者无需处方即可购买。他们使用这些药物来治疗轻微的疾病或症状。一般认为，使用这些药物是安全的，无需医疗保健提供者的监督。

疫苗是用于预防传染病传播的药物。它们刺激人体免疫系统对抗特定病原体。医疗保健提供者通过注射或口服途径接种疫苗。它们对于预防疾病传播至关重要。例如，它们可以预防流感、麻疹、脊髓灰质炎和 COVID-19。

生物制剂是来自生物体或其成分的药物。蛋白质、酶或抗体都是生物制剂的例子。这些药物通常用于治疗癌症、自身免疫性疾病和遗传性疾病等复杂疾病。

仿制药是指与品牌药具有相同活性成分的药物。它们也具有相同的剂型、强度和给药途径。但它们的售价通常低于品牌药。监管机构批准仿制药。但首先，它们的制造商必须证明其与原始品牌药具有生物等效性。

Pharmaceuticals play a critical role in modern 卫生保健. They help to prevent, diagnose, and treat various diseases and conditions. They also improve the health and well-being of millions of people around the world.

药品为何如此重要？

药品之所以必不可少，有几个原因。首先，它们有助于治疗疾病和健康状况。它们对于缓解症状、治愈感染和控制慢性病至关重要。它们改善了全世界数百万人的生活质量。人们使用药物来治疗日常疾病，如过敏、咳嗽和感冒。他们还用它们来治疗癌症、心脏病和糖尿病等严重疾病。药物还可以对抗艾滋病毒/艾滋病等传染病。

药品也为医学研究和创新的进步做出了贡献。这些药物是制药公司大量研发努力的成果。学术机构和其他研究组织也为研发工作做出了贡献。这些努力推动了医学创新。它们使新药、疫苗和疗法的发现和开发成为可能。药物研究导致发现新的治疗方案和改进的配方。它还使人们更好地了解疾病。这些因素有助于医学知识和患者护理的进步。

药品在疾病预防和公共卫生中发挥着重要作用，因此必不可少。它们在防止传染病传播方面发挥着至关重要的作用。例如，疫苗对于保护人们免受疾病侵害至关重要。它们在对抗麻疹、脊髓灰质炎和流感等疾病方面发挥了重要作用。人们也很容易记住它们在 COVID-19 大流行中的作用。纵观历史，疫苗在根除或控制许多致命疾病方面发挥了重要作用。它们是公共卫生工作的基石。

药品可以改善患者的治疗效果和生活质量。它们可以缓解症状并减缓疾病进展。它们还可以预防并发症并降低住院率。这些药物使患者能够控制慢性病并从急性病中恢复过来。因此，他们可以过上更健康的生活。药品还有助于减轻个人、家庭和医疗保健系统的疾病负担。从长远来看，它们可以预防残疾、提高生产力并降低医疗保健成本。

药品必不可少的另一个原因是其经济影响力。它们在创造就业机会方面发挥着重要作用。制药业为全球经济做出了贡献。它创造了数十亿美元的收入，并在全球范围内创造了数百万个就业机会。制药公司投资于研发、制造和分销。这些行动支持经济增长并促进创新。此外，有效药品的供应有助于个人保持健康和高效。它有助于社区和社会的经济福祉。

药品推动了医疗保健的进步和个性化医疗。药品是医疗保健进步不可或缺的一部分。这些进步包括个性化医疗，即根据个人的独特特征量身定制治疗方案。它考虑了遗传、生活方式和病史等因素。这种方法可以实现更精确、更有效的治疗。它可以改善患者的治疗效果。它还减少了医疗保健中对反复试验系统的需求。

Pharmaceuticals Market Research: How Leading Manufacturers Win Launch and Access Decisions

Pharmaceuticals market research has shifted from descriptive reporting to evidence that directly shapes pricing, sequencing, and payer negotiations. The work that matters now happens earlier, deeper in the science, and closer to the prescriber.

Commercial leaders at large manufacturers face a tighter calculus. Indication prioritization, HTA submission evidence, and payer value story development run in parallel rather than in stages. The firms moving fastest treat market research as the connective tissue across medical affairs, market access, and commercial strategy.

What Pharmaceuticals Market Research Now Delivers

Pharmaceuticals market research is the structured collection of clinical, payer, prescriber, and patient evidence used to guide portfolio, launch, and access decisions across a drug’s lifecycle. It blends KOL mapping, patient journey mapping, real-world evidence synthesis, and competitive intelligence into a single decision input.

The work that earns budget is no longer volume tracking. It is research that resolves a specific commercial question: which indication first, which comparator anchors the value story, where biosimilar entry compresses margin, and how formulary positioning shifts when a competitor reads out Phase 3 data.

The Four Decisions Research Must Answer

Across the manufacturers that launch well, four questions recur. Indication sequencing. Payer evidence gaps. Prescriber adoption barriers. Competitive response timing. Research designed around these questions outperforms generic landscape studies on every measure leadership cares about.

Why Launch Sequencing Has Become the Highest-Value Research Question

Launch sequencing decisions now carry more value than pricing decisions for many specialty assets. The reason is structural. A first indication sets the reference price, the payer reimbursement template, and the prescriber anchor for every follow-on indication. Get the first indication wrong and the asset spends its lifecycle correcting an early mispositioning.

The strongest sequencing work combines payer advisory boards, structured prescriber interviews, and competitive intelligence on parallel pipelines. Manufacturers that invested in this discipline early, including Vertex in cystic fibrosis and Regeneron in ophthalmology, built sequencing playbooks that others now study.

According to SIS International Research, indication prioritization studies that integrate payer willingness-to-pay testing with prescriber switching thresholds produce sequencing recommendations that hold up under HTA scrutiny in EU5 markets, where England’s NICE and Germany’s G-BA apply different evidence weights to the same dossier.

How Real-World Evidence Reshapes the Payer Value Story

Payers in the United States, Germany, and France have moved from accepting trial data to demanding real-world evidence on adherence, total cost of care, and comparative effectiveness against standard of care. The payer value story now lives or dies on RWE quality.

The manufacturers winning access conversations build RWE strategies before Phase 3 readout, not after. They identify the comparator data gaps payers will flag, commission claims database studies and chart reviews to fill them, and pressure-test the resulting value story with structured payer interviews across IDNs, regional plans, and national sickness funds.

This matters because payer rejection rarely cites the pivotal trial. It cites the absence of evidence on the populations payers actually cover. Research that anticipates the gap closes it before submission.

What KOL Mapping Looks Like When Done Right

KOL mapping has been diluted by vendors selling lists of names. Useful KOL mapping identifies which clinicians shape guideline language at ASCO, ASH, ESMO, and AHA, which sit on payer P&T committees, and which run the academic centers that anchor referral patterns for a given indication.

The output is not a contact database. It is an influence map showing how a guideline change in one society propagates through formulary decisions, prescriber adoption, and patient access over the following 18 months. Manufacturers that map influence this way time their medical affairs engagement to the moments that matter.

SIS International’s expert interview programs across oncology and rare disease have found that KOL influence concentrates more tightly than most commercial teams assume. In several therapeutic areas, fewer than 30 clinicians globally shape the language that determines reimbursement outcomes across G7 markets.

The SIS Pharmaceuticals Research Decision Framework

Source: SIS International Research

Where Patient Journey Mapping Creates Commercial Lift

Patient journey mapping has matured from a marketing exercise into a commercial diagnostic. The strongest work identifies the specific point at which patients drop out of the diagnosis-to-treatment pathway and quantifies the revenue at stake.

In specialty categories such as multiple sclerosis, IBD, and HER2-positive breast cancer, the gap between diagnosis and appropriate treatment can extend across multiple specialist visits. Each handoff is a leak point. Research that quantifies leak points by geography, payer type, and referral pattern produces the precise inputs medical affairs and field teams need to allocate effort.

This is where ethnographic research and chart audits outperform survey data. Surveys capture what physicians say they do. Chart audits and observation capture what actually happens at the point of care.

How Biosimilar and LOE Intelligence Protects Margin

Loss of exclusivity research has become a continuous discipline rather than a defensive project run in the year before patent expiry. Biosimilar competitive intelligence now starts five to seven years out, tracking development pipelines, manufacturing capacity, and payer policy signals across the United States, EU5, Japan, and emerging markets.

Manufacturers that protect margin best run scenario models that link biosimilar entry probability to formulary tier movement, contracting strategy, and authorized generic decisions. The output is a quarter-by-quarter margin compression timeline that finance, market access, and commercial leadership can plan against.

SIS International’s competitive intelligence engagements across biologics have documented a consistent pattern: the first biosimilar entrant captures meaningful share within twelve months when payer step-edits align with launch, and substantially less when contracting locks the originator into preferred tier status.

What Separates the Strongest Pharmaceuticals Market Research Programs

The manufacturers extracting the most value from research share three habits. They commission research against named decisions, not topic areas. They integrate qualitative depth with quantitative validation rather than choosing between them. They treat international scope as essential, recognizing that a launch decision in the United States is incomplete without parallel evidence from EU5, Japan, China, and Brazil.

Pharmaceuticals market research at this level requires fieldwork capacity in regulated markets, expert interview networks across therapeutic areas, and analytic teams fluent in HTA submission logic. SIS International Research has supported manufacturers across specialty pharmaceuticals, imaging agents, and emerging market entry with mixed-methods programs that integrate prescriber, payer, and patient evidence into single decision-grade deliverables.

The Direction Pharmaceuticals Market Research Is Moving

Three shifts are reshaping the discipline. Research budgets are consolidating around fewer, deeper programs tied to launch and access milestones. RWE is moving from a payer requirement to a commercial input that shapes positioning. And pricing pressure across G7 markets is forcing earlier integration of HTA evidence planning into clinical development.

The manufacturers that lead the next decade will be the ones that treat pharmaceuticals market research as commercial infrastructure rather than a vendor purchase. The evidence base they build now will determine which assets reach peak sales and which stall in access negotiations.

关于 SIS 国际

SIS 国际 提供定量、定性和战略研究。我们提供决策所需的数据、工具、战略、报告和见解。我们还进行访谈、调查、焦点小组和其他市场研究方法和途径。 联系我们 为您的下一个市场研究项目提供帮助。